Katherine Provaznik, DO
Psychiatry · Wethersfield, CTNPI 1376002311
Payments from drug & device makers
What this record shows
This record is dominated by grants: $90,000 of the $90,453 with a category attached, or 99.5%. Biogen accounts for 99.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $90,000 and has fallen 99.6% since, to $348 in 2025. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 7 payments — averaging $12,922 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$90K
- Neuronetics, Inc.$165
- Eisai Inc.$158
- Otsuka America Pharmaceutical, Inc.$105
- Lilly USA, LLC$25
What the payments were for
- Grants$90,00099%
- Food & beverage$4531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 1 | $90,000 |
| Neuronetics, Inc. | 1 | $165 |
| Eisai Inc. | 3 | $158 |
| Otsuka America Pharmaceutical, Inc. | 1 | $105 |
| Lilly USA, LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$165
- Leqembi$112
- REXULTI$105
How this compares
$90,453 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 99 | $788 |
| Clonazepam | 20 | $133 |
| Sertraline Hcl | 26 | $119 |
| Trazodone Hcl | 11 | $57 |
| Lorazepam | 14 | $46 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Wethersfield
- Cherish SmithWethersfield$83K
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.